(b)(4).Medical devices: stent: xience alpine 3.0x15mm(rca), 3.0x28mm, 3.0x15mm(cx).The device was not returned for evaluation.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.The reported patient effect(s) of angina and hypersensitivity are listed in the xience alpine everolimus eluting coronary stent systems instructions for use as known patient effects of coronary stenting procedures.A conclusive cause for the reported patient effects, and the relationship to the product, if any, cannot be determined.There is no indication of a product quality issue with respect to manufacture, design or labeling.
|
It was reported that the patient underwent a successful procedure on (b)(6) 2015 during which one xience alpine stent (3.0 x 15 mm) was deployed successfully in the right coronary artery (rca).Approximately 2-3 months ago the patient began to experience shortness of breath.A stress test confirmed new lesions/blockages located in the circumflex (cx) and the left anterior descending (lad) artery.The stent implant located in the rca was patent.Although the patient had triple artery disease, the decision was made not to perform triple coronary artery bypass, but to perform stenting.On (b)(6) 2017, the patient underwent a new procedure for treatment of the cx and lad.Two xience alpine stents (3.0 x 28 mm and 3.0 x 15 mm) were placed in the cx and one xience alpine stent (2.75 x 15 mm) was placed in the lad.Since that procedure the patient has been experiencing a sensation of tightness in the chest and has to breathe deeply to catch his breath.An ekg was performed; however, nothing of note was found.On (b)(6) 2017, the patients plavix was changed to brilinta.The patient has been feeling light headed with tightness across the chest and also has observed red blotches on his chest.No treatment at this time has been performed.No additional information was provided.
|